Prior Clinical Trials




  • COMPARE-UF will enroll 10,000 women between the ages of 18 and 54 who have been diagnosed with fibroids.
  • Women make their own decisions with their doctor about the treatment that is best for them.
  • COMPARE-UF gathers information about symptoms before and, for a minimum of three years, after treatment for their fibroids.
  • COMPARE-UF will use the information that we learn from women with fibroids to improve patient care and to help women make informed treatment decisions.

Am I eligible?

You may be eligible to join the study if you:

  • Are a woman, between the ages of 18-54 years of age
  • Have been diagnosed with uterine fibroids
  • Are scheduled to undergo a procedure to treat uterine fibroids

How can I enroll in the COMPARE-UF study?

If you are interested in enrolling in COMPARE-UF, please contact our research coordinators at 415-297-3114 or [email protected].

The PLUM Trial: New Study of Medication to Treat Fibroids

WE ARE NOT CURRENTLY ENROLLING IN THE PLUM study. Details provided for information only.

What is PLUM?

The PLUM study (Pilot of Letrozole to treat Uterine Leiomyoma) is a study of a medication called letrozole to treat uterine fibroids. You may be eligible for the stud if you are:

  1. Are a premenopausal woman
  2. Have fibroids that cause significant symptoms

What is letrozole?

Letrozole is a pill that is used for many different purposes in women’s health including treatment of infertility, endometriosis, and uterine fibroids. Letrozole is a non-hormonal medication called an aromatase inhibitor. Letrozole works by shrinking down fibroid size to improve fibroid-related symptoms. Although letrozole is used to treat some gynecologic conditions, it is approved by the FDA for a different purpose: to treat postmenopausal women with hormone sensitive breast cancer. Therefore, in this study, the use of letrozole in considered investigational (not FDA approved).

Why is this study being done?

Although some gynecologists use letrozole in their clinical practice to treat women with fibroids, there have been very few studies to evaluate the effectiveness of treatment. This goal of this study is to understand how the use of letrozole impacts fibroid-related symptoms and fibroid size.

Can my fibroids be treated with letrozole?

Women who are having symptoms related to fibroids such as heavy bleeding, pelvic pressure, or urinary frequency may be eligible for treatment with letrozole. At your initial visit, you and the gynecologist will discuss your symptoms and your treatment goals, and review the position and size of your fibroids with radiology imaging (pelvic ultrasound and/or MRI). We will also review with you other possible treatment options for your fibroid-related symptoms including nonsurgical and surgical options.

How can I make an appointment for to discuss enrolling in the PLUM study of letrozole?

If you are interested in letrozole treatment for fibroids, please contact our research coordinators at 415-297-3114 or [email protected].


Visit our ULTRA Study website for complete details.

What is the ULTRA Study?

WE ARE NOT CURRENTLY ENROLLING IN THE ULTRA study. Details provided for information only.

THE ULTRA STUDY is a study of a new, FDA approved fibroid treatment called radiofrequency ablation (Acessa™) . This procedure uses heat to destroy fibroid tissue during a laparoscopic surgery. Women return home on the same day as the procedure and are back to their normal activities in 5-9 days. The goal of the study is to evaluate how fibroid symptoms change over time after radiofrequency ablation (Acessa™) . If you participate in the ULTRA study, you will receive radiofrequency ablation (Acessa™) and complete questionnaires about your fibroid symptoms and reproductive health.  You may be eligible to participate in the study if you:

  1. Are at least 21 years of age
  2. Have uterine fibroids that cause heavy bleeding, pelvic pressure or discomfort, urinary or bowel symptoms, or dyspareunia (painful sexual intercourse)
  3. Are able to undergo laparoscopic surgery

Read more about the ULTRA study at the NIH U.S. National Library of Medicine's page on Clinical Trials.

If you are interested in participating in ULTRA, please contact the study coordinator at 415-297-3114 or by e-mail: [email protected]


WE ARE NOT CURRENTLY ENROLLING IN THE FIRSTT study. Details provided for information only.

UCSF is participating with Mayo Clinic and Duke University in a study funded by the National Institutes of Health to compare uterine artery embolization (UAE) and MR-guided focused ultrasound (MRgFUS) for the treatment of uterine fibroids. This is the first-ever study in the United States which compares MRgFUS to uterine artery embolization.

The study, called Interventions: Reducing Symptoms Today and Tomorrow (FIRSTT) will randomly assign 220 women with symptomatic uterine fibroids to be treated with either MRgFUS or UAE.

The study will follow patients for one year to assess differences between the treatments in fibroid symptom relief, absence of side effects, changes in quality of life, and the need for additional fibroid treatment.

Both treatments are approved by the Food and Drug Administration (FDA) for women who do not plan to become pregnant.

You may qualify for the FIRSTT study if you are:

  • Premenopausal
  • At least 25 years old
  • Willing to undergo either UAE or MRgFUS

Read more about the FIRSTT study at the NIH U.S. National Library of Medicine's page on Clinical Trials.

Please contact the study coordinator at 415-297-3114 or e-mail: [email protected]

Thank you for your interest in our research study.